When diabetes causes CKD, it’s sometimes called diabetic kidney disease. Elevated blood sugar levels that result from diabetes can damage the tiny blood vessels inside your kidneys. As a result, your ...

If you are living with Type 2 diabetes, you certainly are not alone. One in 10 people in the U.S. has diabetes, according to the CDC. However, despite considerable progress in diabetes treatment over ...

Researchers developed a model using routine clinical data to identify optimal glucose-lowering therapies for patients with type 2 diabetes (T2D). Individuals receiving model-predicted optimal therapy ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of ...

Oral semaglutide (Rybelsus, Novo Nordisk) lowered hemoglobin A1c more than empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) in a recently published open-label, head-to-head comparison of the type ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows. Not only is ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

Semaglutide, the active ingredient in Ozempic, and other drugs in the same class have revolutionized the treatment of obesity and type 2 diabetes. Now, a clinical trial suggests the medicines can ...

Medicare Part D spending on diabetes drugs increased 364% from 2019 to 2023, driven by GLP-1 and SGLT-2 inhibitors. Metformin spending decreased by 5%, contrasting with the surge in other diabetes ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. Obesity drugs were first approved to treat type ...